Multispecific Antibodies Targeting HLA-A2/MAGE-A4 Cancer Therapy
Summary
USPTO published Roche/Genentech patent application US20260098095A1 disclosing multispecific antibodies binding to HLA-A2/MAGE-A4 complex for T cell activation in cancer treatment. The application covers antibody compositions, encoding polynucleotides, production methods, and therapeutic uses. The invention addresses immunotherapy approaches for HLA-A2-positive tumors expressing MAGE-A4 antigen.
What changed
USPTO published Roche/Genentech patent application US20260098095A1 disclosing multispecific antibodies that bind to the HLA-A2/MAGE-A4 antigen complex. The application claims antibodies, antibody fragments, multispecific formats, polynucleotides encoding such antibodies, vectors, host cells, and methods of use for treating disease, particularly cancer. CPC classifications indicate therapeutic application (A61P 35/00) and antibody technology (C07K 16/28, C07K 16/30).
Pharmaceutical and biotech companies developing T cell-engaging immunotherapies or HLA-A2-targeted cancer treatments should monitor this application's prosecution for claim scope that may affect their programs. The patent, if granted, could impose licensing requirements or necessitate design-around strategies for competing therapeutic approaches.
What to do next
- Monitor for eventual patent grant and claim scope
- Review antibody designs for potential licensing implications
- Assess freedom-to-operate for HLA-A2/MAGE-A4 immunotherapy programs
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODIES BINDING TO HLA-A2/MAGE-A4
Application US20260098095A1 Kind: A1 Apr 09, 2026
Inventors
Tina WEINZIERL, Lydia Jasmin HANISCH, Alexander BUJOTZEK, Alejandro CARPY GUTIERREZ CIRLOS, Stefan KLOSTERMANN, Christian KLEIN, Simon Patrick KEISER, Tanja FAUTI, Estelle MARRER-BERGER, Pablo UMAÑA
Abstract
The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
CPC Classifications
C07K 16/2833 A61P 35/00 C07K 16/2809 C07K 16/30 A61K 2039/505 C07K 2317/31 C07K 2317/55 C07K 2317/73 C07K 2317/92
Filing Date
2025-09-16
Application No.
19330067
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.